Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 07:00 ET | Source: Forward Therapeutics

Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor

Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor